Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 15/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968229 | 0.93 | PTGER4 (0.67) | PTGER4CYP1A2CYP2D6KMT2APPARG | |
| SCHEMBL3963817 | 0.91 | PTGER4 (0.82) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3562781 | 0.90 | PTGER4 (0.84) | PTGER4CYP1A2CYP2D6ALDH1A1POLB | |
| SCHEMBL3566476 | 0.89 | PTGER4 (1.00) | PTGER4CYP1A2CYP2D6ALDH1A1POLB | |
| SCHEMBL13594717 | 0.89 | PTGER4 (0.62) | PTGER4CYP1A2CYP2D6ALDH1A1POLB | |
| SCHEMBL1589990 | 0.87 | PTGER4 (0.83) | PTGER4CYP1A2CYP2D6ALDH1A1POLB | |
| SCHEMBL3564798 | 0.86 | PTGER4 (0.76) | PTGER4CYP1A2CYP2D6POLBKMT2A | |
| SCHEMBL13594954 | 0.85 | PTGER4 (0.56) | PTGER4CYP1A2CYP2D6ALDH1A1POLB | |
| SCHEMBL3557608 | 0.85 | PTGER4 (0.91) | PTGER4CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL4409667 | 0.84 | PTGER4 (0.88) | PTGER4CYP1A2CYP2D6ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | claimed |
| EP-2081896-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | claimed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | claimed |
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| EP-2081896-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318523-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER3, HTR4 | PTGER4 1/4885CYP1A2 328/4885CYP2D6 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.